European Health Policy Mountain Retreat Event Goes Global 01/10/2018 Health Policy Watch Dorli Kahr-Gottlieb writes: For more than 20 years, every October, around 500 leading health experts from governmental institutions, civil society, the academic world, and the private sector meet up at the European Health Forum Gastein (EHFG). They meet to discuss Europe’s contemporary health challenges and address pressing issues around the sustainability of European health systems in a Davos like setting, in the presence of Ministers of Health and senior European Commission and WHO officials. This year’s edition of the EHFG, called simply “Gastein” by the cognoscente, is an official Austrian EU Presidency event. Over the three days, Gastein is not going to shy away from the big European political debates such as how much of a role Europe should play in shaping health policy; but also it is going to take on some of the big global health policy challenges. Continue reading -> New Analysis Reveals Significant Gaps In Funding For Health Innovation 04/09/2018 Leila Ueberschlag Many of the products critically needed to fight some of the world’s most prevalent infectious diseases are not likely to be developed. This is the outcome of a new analysis, which reveals significant gaps in funding for health innovation. Continue reading -> New Paper Looks At Debate On Generic Medicines Of Biological Origin 23/08/2018 Leila Ueberschlag “Whether or not there is an adequate supply of generic biological drugs available will be crucial to ensuring the economic viability of health systems in both developing and developed countries.” So writes the South Centre – an intergovernmental organisation that helps developing countries to combine their efforts and expertise to promote their common interests in the international arena – in a newly published Policy Brief dedicated to the international debate on generic medicines of biological origin. Continue reading -> Study Shows Pharmaceutical Industry Investing In Basic Research, Some Questions Remain Open 12/07/2018 Catherine Saez Basic research in health is often conducted by public universities or institutions, and public health activists have underlined the view that because research is funded by public money, medicines should not be so highly priced. A new study by an independent economic research institute shows that the pharmaceutical industry is a substantial partner in research activities and its investment in basic research is growing. The study, however, falls short of providing answers to key questions such as what is included in research and development figures, or what kind of basic research is conducted. Continue reading -> First Results Of Pharma-Led Initiative To Increase Access To Treatments 29/06/2018 Catherine Saez Early results of a biopharmaceutical companies-based initiative to encourage access to treatment in developing countries shows a focus on cancer, diabetes, and cardiovascular disease, through 62 programmes. The report, conducted by an independent observatory, provides key findings on several areas, including local priorities, and social inequity. Continue reading -> The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa 18/06/2018 Patralekha Chatterjee Dr Carlos Maria Correa, an Argentinian economist and lawyer, is globally renowned for his expertise on international trade, intellectual property, health, technology transfer, investment policy and especially their impact on developing countries. He has authored several books and academic articles and been a visiting professor at several universities. Additionally, he has consulted with many United Nations agencies, the World Bank, and other regional and international organisations and has advised several governments on intellectual property, innovation policy and public health. Correa was a member of the UK Commission on Intellectual Property, of the Commission on Intellectual Property, Innovation and Public Health established by the World Health Assembly and of the FAO Panel of Eminent Experts on Ethics in Food and Agriculture. Currently, he is the Director of the Centre for Interdisciplinary Studies on Industrial Property and Economics Law, at the University of Buenos Aires. He takes over as the Executive Director of the Secretariat of the Geneva-based South Centre from 1 July 2018. Correa recently engaged in an interview with Patralekha Chatterjee for Intellectual Property Watch. [Note: this interview is number two of two. The first, with Dr Othoman Mellouk, is available here.] Continue reading -> The Myth Behind Health And Trade Agreements: Q&A With Othoman Mellouk 15/06/2018 Patralekha Chatterjee Dr Othoman Mellouk is a Moroccan treatment advocate who has been working on intellectual property and access to medicines for more than a decade. He is the Intellectual Property and Access to Medicines Lead at the international treatment preparedness coalition (ITPC), a global network of people living with HIV and their advocates working together to achieve access to HIV and Viral Hepatitis and a member of the WHO Strategic and Technical Advisory Committee on HIV and Hepatitis. Dr Mellouk started off in the Association for the Fight against AIDS which has been at the forefront of the response to HIV in Morocco and the introduction of the first anti-HIV generic medicines in the country. In a series supported by the Make Medicines Affordable organisation, Mellouk recently engaged in an interview with Patralekha Chatterjee for Intellectual Property Watch. Continue reading -> Pharma Industry To South Africa: ‘We Are The Goose That Lays The Golden Egg’ 11/06/2018 Linda Daniels Following the South African government's recent approval of a new intellectual property policy that includes elements aimed at preserving access to medical products that are increasing in popularity among developing countries, the research-based pharmaceutical industry had a few general comments. The message: the policy incorporates some of their concerns but is wrong on "evergreening" patents, and could harm industry, which is "the goose that lays the golden egg." Continue reading -> Substandard, Falsified Medicines Not About IP, Geneva Experts Say 06/06/2018 Catherine Saez Falsified and substandard medical products continue to be a global concern, and how those products are characterised is important to avoid confusion, particularly with intellectual property rights infringement. A panel convened by Brazil, India and South Africa yesterday at the World Trade Organization looked at the implications of a new definition of such products at the neighbouring World Health Organization. Continue reading -> World Health Assembly Agrees To Reinvigorate Plan Of Action To Boost R&D, Access 25/05/2018 Catherine Saez Ten years after the adoption of a World Health Organization plan of action meant to stimulate innovation for diseases that disproportionately affect developing countries, and with very little to show for it since, delegates at the World Health Assembly this week agreed to a number of recommendations to reinvigorate the effort. How to finance the implementation of those recommendations, however, is unclear. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
New Analysis Reveals Significant Gaps In Funding For Health Innovation 04/09/2018 Leila Ueberschlag Many of the products critically needed to fight some of the world’s most prevalent infectious diseases are not likely to be developed. This is the outcome of a new analysis, which reveals significant gaps in funding for health innovation. Continue reading -> New Paper Looks At Debate On Generic Medicines Of Biological Origin 23/08/2018 Leila Ueberschlag “Whether or not there is an adequate supply of generic biological drugs available will be crucial to ensuring the economic viability of health systems in both developing and developed countries.” So writes the South Centre – an intergovernmental organisation that helps developing countries to combine their efforts and expertise to promote their common interests in the international arena – in a newly published Policy Brief dedicated to the international debate on generic medicines of biological origin. Continue reading -> Study Shows Pharmaceutical Industry Investing In Basic Research, Some Questions Remain Open 12/07/2018 Catherine Saez Basic research in health is often conducted by public universities or institutions, and public health activists have underlined the view that because research is funded by public money, medicines should not be so highly priced. A new study by an independent economic research institute shows that the pharmaceutical industry is a substantial partner in research activities and its investment in basic research is growing. The study, however, falls short of providing answers to key questions such as what is included in research and development figures, or what kind of basic research is conducted. Continue reading -> First Results Of Pharma-Led Initiative To Increase Access To Treatments 29/06/2018 Catherine Saez Early results of a biopharmaceutical companies-based initiative to encourage access to treatment in developing countries shows a focus on cancer, diabetes, and cardiovascular disease, through 62 programmes. The report, conducted by an independent observatory, provides key findings on several areas, including local priorities, and social inequity. Continue reading -> The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa 18/06/2018 Patralekha Chatterjee Dr Carlos Maria Correa, an Argentinian economist and lawyer, is globally renowned for his expertise on international trade, intellectual property, health, technology transfer, investment policy and especially their impact on developing countries. He has authored several books and academic articles and been a visiting professor at several universities. Additionally, he has consulted with many United Nations agencies, the World Bank, and other regional and international organisations and has advised several governments on intellectual property, innovation policy and public health. Correa was a member of the UK Commission on Intellectual Property, of the Commission on Intellectual Property, Innovation and Public Health established by the World Health Assembly and of the FAO Panel of Eminent Experts on Ethics in Food and Agriculture. Currently, he is the Director of the Centre for Interdisciplinary Studies on Industrial Property and Economics Law, at the University of Buenos Aires. He takes over as the Executive Director of the Secretariat of the Geneva-based South Centre from 1 July 2018. Correa recently engaged in an interview with Patralekha Chatterjee for Intellectual Property Watch. [Note: this interview is number two of two. The first, with Dr Othoman Mellouk, is available here.] Continue reading -> The Myth Behind Health And Trade Agreements: Q&A With Othoman Mellouk 15/06/2018 Patralekha Chatterjee Dr Othoman Mellouk is a Moroccan treatment advocate who has been working on intellectual property and access to medicines for more than a decade. He is the Intellectual Property and Access to Medicines Lead at the international treatment preparedness coalition (ITPC), a global network of people living with HIV and their advocates working together to achieve access to HIV and Viral Hepatitis and a member of the WHO Strategic and Technical Advisory Committee on HIV and Hepatitis. Dr Mellouk started off in the Association for the Fight against AIDS which has been at the forefront of the response to HIV in Morocco and the introduction of the first anti-HIV generic medicines in the country. In a series supported by the Make Medicines Affordable organisation, Mellouk recently engaged in an interview with Patralekha Chatterjee for Intellectual Property Watch. Continue reading -> Pharma Industry To South Africa: ‘We Are The Goose That Lays The Golden Egg’ 11/06/2018 Linda Daniels Following the South African government's recent approval of a new intellectual property policy that includes elements aimed at preserving access to medical products that are increasing in popularity among developing countries, the research-based pharmaceutical industry had a few general comments. The message: the policy incorporates some of their concerns but is wrong on "evergreening" patents, and could harm industry, which is "the goose that lays the golden egg." Continue reading -> Substandard, Falsified Medicines Not About IP, Geneva Experts Say 06/06/2018 Catherine Saez Falsified and substandard medical products continue to be a global concern, and how those products are characterised is important to avoid confusion, particularly with intellectual property rights infringement. A panel convened by Brazil, India and South Africa yesterday at the World Trade Organization looked at the implications of a new definition of such products at the neighbouring World Health Organization. Continue reading -> World Health Assembly Agrees To Reinvigorate Plan Of Action To Boost R&D, Access 25/05/2018 Catherine Saez Ten years after the adoption of a World Health Organization plan of action meant to stimulate innovation for diseases that disproportionately affect developing countries, and with very little to show for it since, delegates at the World Health Assembly this week agreed to a number of recommendations to reinvigorate the effort. How to finance the implementation of those recommendations, however, is unclear. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
New Paper Looks At Debate On Generic Medicines Of Biological Origin 23/08/2018 Leila Ueberschlag “Whether or not there is an adequate supply of generic biological drugs available will be crucial to ensuring the economic viability of health systems in both developing and developed countries.” So writes the South Centre – an intergovernmental organisation that helps developing countries to combine their efforts and expertise to promote their common interests in the international arena – in a newly published Policy Brief dedicated to the international debate on generic medicines of biological origin. Continue reading -> Study Shows Pharmaceutical Industry Investing In Basic Research, Some Questions Remain Open 12/07/2018 Catherine Saez Basic research in health is often conducted by public universities or institutions, and public health activists have underlined the view that because research is funded by public money, medicines should not be so highly priced. A new study by an independent economic research institute shows that the pharmaceutical industry is a substantial partner in research activities and its investment in basic research is growing. The study, however, falls short of providing answers to key questions such as what is included in research and development figures, or what kind of basic research is conducted. Continue reading -> First Results Of Pharma-Led Initiative To Increase Access To Treatments 29/06/2018 Catherine Saez Early results of a biopharmaceutical companies-based initiative to encourage access to treatment in developing countries shows a focus on cancer, diabetes, and cardiovascular disease, through 62 programmes. The report, conducted by an independent observatory, provides key findings on several areas, including local priorities, and social inequity. Continue reading -> The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa 18/06/2018 Patralekha Chatterjee Dr Carlos Maria Correa, an Argentinian economist and lawyer, is globally renowned for his expertise on international trade, intellectual property, health, technology transfer, investment policy and especially their impact on developing countries. He has authored several books and academic articles and been a visiting professor at several universities. Additionally, he has consulted with many United Nations agencies, the World Bank, and other regional and international organisations and has advised several governments on intellectual property, innovation policy and public health. Correa was a member of the UK Commission on Intellectual Property, of the Commission on Intellectual Property, Innovation and Public Health established by the World Health Assembly and of the FAO Panel of Eminent Experts on Ethics in Food and Agriculture. Currently, he is the Director of the Centre for Interdisciplinary Studies on Industrial Property and Economics Law, at the University of Buenos Aires. He takes over as the Executive Director of the Secretariat of the Geneva-based South Centre from 1 July 2018. Correa recently engaged in an interview with Patralekha Chatterjee for Intellectual Property Watch. [Note: this interview is number two of two. The first, with Dr Othoman Mellouk, is available here.] Continue reading -> The Myth Behind Health And Trade Agreements: Q&A With Othoman Mellouk 15/06/2018 Patralekha Chatterjee Dr Othoman Mellouk is a Moroccan treatment advocate who has been working on intellectual property and access to medicines for more than a decade. He is the Intellectual Property and Access to Medicines Lead at the international treatment preparedness coalition (ITPC), a global network of people living with HIV and their advocates working together to achieve access to HIV and Viral Hepatitis and a member of the WHO Strategic and Technical Advisory Committee on HIV and Hepatitis. Dr Mellouk started off in the Association for the Fight against AIDS which has been at the forefront of the response to HIV in Morocco and the introduction of the first anti-HIV generic medicines in the country. In a series supported by the Make Medicines Affordable organisation, Mellouk recently engaged in an interview with Patralekha Chatterjee for Intellectual Property Watch. Continue reading -> Pharma Industry To South Africa: ‘We Are The Goose That Lays The Golden Egg’ 11/06/2018 Linda Daniels Following the South African government's recent approval of a new intellectual property policy that includes elements aimed at preserving access to medical products that are increasing in popularity among developing countries, the research-based pharmaceutical industry had a few general comments. The message: the policy incorporates some of their concerns but is wrong on "evergreening" patents, and could harm industry, which is "the goose that lays the golden egg." Continue reading -> Substandard, Falsified Medicines Not About IP, Geneva Experts Say 06/06/2018 Catherine Saez Falsified and substandard medical products continue to be a global concern, and how those products are characterised is important to avoid confusion, particularly with intellectual property rights infringement. A panel convened by Brazil, India and South Africa yesterday at the World Trade Organization looked at the implications of a new definition of such products at the neighbouring World Health Organization. Continue reading -> World Health Assembly Agrees To Reinvigorate Plan Of Action To Boost R&D, Access 25/05/2018 Catherine Saez Ten years after the adoption of a World Health Organization plan of action meant to stimulate innovation for diseases that disproportionately affect developing countries, and with very little to show for it since, delegates at the World Health Assembly this week agreed to a number of recommendations to reinvigorate the effort. How to finance the implementation of those recommendations, however, is unclear. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Study Shows Pharmaceutical Industry Investing In Basic Research, Some Questions Remain Open 12/07/2018 Catherine Saez Basic research in health is often conducted by public universities or institutions, and public health activists have underlined the view that because research is funded by public money, medicines should not be so highly priced. A new study by an independent economic research institute shows that the pharmaceutical industry is a substantial partner in research activities and its investment in basic research is growing. The study, however, falls short of providing answers to key questions such as what is included in research and development figures, or what kind of basic research is conducted. Continue reading -> First Results Of Pharma-Led Initiative To Increase Access To Treatments 29/06/2018 Catherine Saez Early results of a biopharmaceutical companies-based initiative to encourage access to treatment in developing countries shows a focus on cancer, diabetes, and cardiovascular disease, through 62 programmes. The report, conducted by an independent observatory, provides key findings on several areas, including local priorities, and social inequity. Continue reading -> The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa 18/06/2018 Patralekha Chatterjee Dr Carlos Maria Correa, an Argentinian economist and lawyer, is globally renowned for his expertise on international trade, intellectual property, health, technology transfer, investment policy and especially their impact on developing countries. He has authored several books and academic articles and been a visiting professor at several universities. Additionally, he has consulted with many United Nations agencies, the World Bank, and other regional and international organisations and has advised several governments on intellectual property, innovation policy and public health. Correa was a member of the UK Commission on Intellectual Property, of the Commission on Intellectual Property, Innovation and Public Health established by the World Health Assembly and of the FAO Panel of Eminent Experts on Ethics in Food and Agriculture. Currently, he is the Director of the Centre for Interdisciplinary Studies on Industrial Property and Economics Law, at the University of Buenos Aires. He takes over as the Executive Director of the Secretariat of the Geneva-based South Centre from 1 July 2018. Correa recently engaged in an interview with Patralekha Chatterjee for Intellectual Property Watch. [Note: this interview is number two of two. The first, with Dr Othoman Mellouk, is available here.] Continue reading -> The Myth Behind Health And Trade Agreements: Q&A With Othoman Mellouk 15/06/2018 Patralekha Chatterjee Dr Othoman Mellouk is a Moroccan treatment advocate who has been working on intellectual property and access to medicines for more than a decade. He is the Intellectual Property and Access to Medicines Lead at the international treatment preparedness coalition (ITPC), a global network of people living with HIV and their advocates working together to achieve access to HIV and Viral Hepatitis and a member of the WHO Strategic and Technical Advisory Committee on HIV and Hepatitis. Dr Mellouk started off in the Association for the Fight against AIDS which has been at the forefront of the response to HIV in Morocco and the introduction of the first anti-HIV generic medicines in the country. In a series supported by the Make Medicines Affordable organisation, Mellouk recently engaged in an interview with Patralekha Chatterjee for Intellectual Property Watch. Continue reading -> Pharma Industry To South Africa: ‘We Are The Goose That Lays The Golden Egg’ 11/06/2018 Linda Daniels Following the South African government's recent approval of a new intellectual property policy that includes elements aimed at preserving access to medical products that are increasing in popularity among developing countries, the research-based pharmaceutical industry had a few general comments. The message: the policy incorporates some of their concerns but is wrong on "evergreening" patents, and could harm industry, which is "the goose that lays the golden egg." Continue reading -> Substandard, Falsified Medicines Not About IP, Geneva Experts Say 06/06/2018 Catherine Saez Falsified and substandard medical products continue to be a global concern, and how those products are characterised is important to avoid confusion, particularly with intellectual property rights infringement. A panel convened by Brazil, India and South Africa yesterday at the World Trade Organization looked at the implications of a new definition of such products at the neighbouring World Health Organization. Continue reading -> World Health Assembly Agrees To Reinvigorate Plan Of Action To Boost R&D, Access 25/05/2018 Catherine Saez Ten years after the adoption of a World Health Organization plan of action meant to stimulate innovation for diseases that disproportionately affect developing countries, and with very little to show for it since, delegates at the World Health Assembly this week agreed to a number of recommendations to reinvigorate the effort. How to finance the implementation of those recommendations, however, is unclear. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
First Results Of Pharma-Led Initiative To Increase Access To Treatments 29/06/2018 Catherine Saez Early results of a biopharmaceutical companies-based initiative to encourage access to treatment in developing countries shows a focus on cancer, diabetes, and cardiovascular disease, through 62 programmes. The report, conducted by an independent observatory, provides key findings on several areas, including local priorities, and social inequity. Continue reading -> The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa 18/06/2018 Patralekha Chatterjee Dr Carlos Maria Correa, an Argentinian economist and lawyer, is globally renowned for his expertise on international trade, intellectual property, health, technology transfer, investment policy and especially their impact on developing countries. He has authored several books and academic articles and been a visiting professor at several universities. Additionally, he has consulted with many United Nations agencies, the World Bank, and other regional and international organisations and has advised several governments on intellectual property, innovation policy and public health. Correa was a member of the UK Commission on Intellectual Property, of the Commission on Intellectual Property, Innovation and Public Health established by the World Health Assembly and of the FAO Panel of Eminent Experts on Ethics in Food and Agriculture. Currently, he is the Director of the Centre for Interdisciplinary Studies on Industrial Property and Economics Law, at the University of Buenos Aires. He takes over as the Executive Director of the Secretariat of the Geneva-based South Centre from 1 July 2018. Correa recently engaged in an interview with Patralekha Chatterjee for Intellectual Property Watch. [Note: this interview is number two of two. The first, with Dr Othoman Mellouk, is available here.] Continue reading -> The Myth Behind Health And Trade Agreements: Q&A With Othoman Mellouk 15/06/2018 Patralekha Chatterjee Dr Othoman Mellouk is a Moroccan treatment advocate who has been working on intellectual property and access to medicines for more than a decade. He is the Intellectual Property and Access to Medicines Lead at the international treatment preparedness coalition (ITPC), a global network of people living with HIV and their advocates working together to achieve access to HIV and Viral Hepatitis and a member of the WHO Strategic and Technical Advisory Committee on HIV and Hepatitis. Dr Mellouk started off in the Association for the Fight against AIDS which has been at the forefront of the response to HIV in Morocco and the introduction of the first anti-HIV generic medicines in the country. In a series supported by the Make Medicines Affordable organisation, Mellouk recently engaged in an interview with Patralekha Chatterjee for Intellectual Property Watch. Continue reading -> Pharma Industry To South Africa: ‘We Are The Goose That Lays The Golden Egg’ 11/06/2018 Linda Daniels Following the South African government's recent approval of a new intellectual property policy that includes elements aimed at preserving access to medical products that are increasing in popularity among developing countries, the research-based pharmaceutical industry had a few general comments. The message: the policy incorporates some of their concerns but is wrong on "evergreening" patents, and could harm industry, which is "the goose that lays the golden egg." Continue reading -> Substandard, Falsified Medicines Not About IP, Geneva Experts Say 06/06/2018 Catherine Saez Falsified and substandard medical products continue to be a global concern, and how those products are characterised is important to avoid confusion, particularly with intellectual property rights infringement. A panel convened by Brazil, India and South Africa yesterday at the World Trade Organization looked at the implications of a new definition of such products at the neighbouring World Health Organization. Continue reading -> World Health Assembly Agrees To Reinvigorate Plan Of Action To Boost R&D, Access 25/05/2018 Catherine Saez Ten years after the adoption of a World Health Organization plan of action meant to stimulate innovation for diseases that disproportionately affect developing countries, and with very little to show for it since, delegates at the World Health Assembly this week agreed to a number of recommendations to reinvigorate the effort. How to finance the implementation of those recommendations, however, is unclear. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa 18/06/2018 Patralekha Chatterjee Dr Carlos Maria Correa, an Argentinian economist and lawyer, is globally renowned for his expertise on international trade, intellectual property, health, technology transfer, investment policy and especially their impact on developing countries. He has authored several books and academic articles and been a visiting professor at several universities. Additionally, he has consulted with many United Nations agencies, the World Bank, and other regional and international organisations and has advised several governments on intellectual property, innovation policy and public health. Correa was a member of the UK Commission on Intellectual Property, of the Commission on Intellectual Property, Innovation and Public Health established by the World Health Assembly and of the FAO Panel of Eminent Experts on Ethics in Food and Agriculture. Currently, he is the Director of the Centre for Interdisciplinary Studies on Industrial Property and Economics Law, at the University of Buenos Aires. He takes over as the Executive Director of the Secretariat of the Geneva-based South Centre from 1 July 2018. Correa recently engaged in an interview with Patralekha Chatterjee for Intellectual Property Watch. [Note: this interview is number two of two. The first, with Dr Othoman Mellouk, is available here.] Continue reading -> The Myth Behind Health And Trade Agreements: Q&A With Othoman Mellouk 15/06/2018 Patralekha Chatterjee Dr Othoman Mellouk is a Moroccan treatment advocate who has been working on intellectual property and access to medicines for more than a decade. He is the Intellectual Property and Access to Medicines Lead at the international treatment preparedness coalition (ITPC), a global network of people living with HIV and their advocates working together to achieve access to HIV and Viral Hepatitis and a member of the WHO Strategic and Technical Advisory Committee on HIV and Hepatitis. Dr Mellouk started off in the Association for the Fight against AIDS which has been at the forefront of the response to HIV in Morocco and the introduction of the first anti-HIV generic medicines in the country. In a series supported by the Make Medicines Affordable organisation, Mellouk recently engaged in an interview with Patralekha Chatterjee for Intellectual Property Watch. Continue reading -> Pharma Industry To South Africa: ‘We Are The Goose That Lays The Golden Egg’ 11/06/2018 Linda Daniels Following the South African government's recent approval of a new intellectual property policy that includes elements aimed at preserving access to medical products that are increasing in popularity among developing countries, the research-based pharmaceutical industry had a few general comments. The message: the policy incorporates some of their concerns but is wrong on "evergreening" patents, and could harm industry, which is "the goose that lays the golden egg." Continue reading -> Substandard, Falsified Medicines Not About IP, Geneva Experts Say 06/06/2018 Catherine Saez Falsified and substandard medical products continue to be a global concern, and how those products are characterised is important to avoid confusion, particularly with intellectual property rights infringement. A panel convened by Brazil, India and South Africa yesterday at the World Trade Organization looked at the implications of a new definition of such products at the neighbouring World Health Organization. Continue reading -> World Health Assembly Agrees To Reinvigorate Plan Of Action To Boost R&D, Access 25/05/2018 Catherine Saez Ten years after the adoption of a World Health Organization plan of action meant to stimulate innovation for diseases that disproportionately affect developing countries, and with very little to show for it since, delegates at the World Health Assembly this week agreed to a number of recommendations to reinvigorate the effort. How to finance the implementation of those recommendations, however, is unclear. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
The Myth Behind Health And Trade Agreements: Q&A With Othoman Mellouk 15/06/2018 Patralekha Chatterjee Dr Othoman Mellouk is a Moroccan treatment advocate who has been working on intellectual property and access to medicines for more than a decade. He is the Intellectual Property and Access to Medicines Lead at the international treatment preparedness coalition (ITPC), a global network of people living with HIV and their advocates working together to achieve access to HIV and Viral Hepatitis and a member of the WHO Strategic and Technical Advisory Committee on HIV and Hepatitis. Dr Mellouk started off in the Association for the Fight against AIDS which has been at the forefront of the response to HIV in Morocco and the introduction of the first anti-HIV generic medicines in the country. In a series supported by the Make Medicines Affordable organisation, Mellouk recently engaged in an interview with Patralekha Chatterjee for Intellectual Property Watch. Continue reading -> Pharma Industry To South Africa: ‘We Are The Goose That Lays The Golden Egg’ 11/06/2018 Linda Daniels Following the South African government's recent approval of a new intellectual property policy that includes elements aimed at preserving access to medical products that are increasing in popularity among developing countries, the research-based pharmaceutical industry had a few general comments. The message: the policy incorporates some of their concerns but is wrong on "evergreening" patents, and could harm industry, which is "the goose that lays the golden egg." Continue reading -> Substandard, Falsified Medicines Not About IP, Geneva Experts Say 06/06/2018 Catherine Saez Falsified and substandard medical products continue to be a global concern, and how those products are characterised is important to avoid confusion, particularly with intellectual property rights infringement. A panel convened by Brazil, India and South Africa yesterday at the World Trade Organization looked at the implications of a new definition of such products at the neighbouring World Health Organization. Continue reading -> World Health Assembly Agrees To Reinvigorate Plan Of Action To Boost R&D, Access 25/05/2018 Catherine Saez Ten years after the adoption of a World Health Organization plan of action meant to stimulate innovation for diseases that disproportionately affect developing countries, and with very little to show for it since, delegates at the World Health Assembly this week agreed to a number of recommendations to reinvigorate the effort. How to finance the implementation of those recommendations, however, is unclear. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Pharma Industry To South Africa: ‘We Are The Goose That Lays The Golden Egg’ 11/06/2018 Linda Daniels Following the South African government's recent approval of a new intellectual property policy that includes elements aimed at preserving access to medical products that are increasing in popularity among developing countries, the research-based pharmaceutical industry had a few general comments. The message: the policy incorporates some of their concerns but is wrong on "evergreening" patents, and could harm industry, which is "the goose that lays the golden egg." Continue reading -> Substandard, Falsified Medicines Not About IP, Geneva Experts Say 06/06/2018 Catherine Saez Falsified and substandard medical products continue to be a global concern, and how those products are characterised is important to avoid confusion, particularly with intellectual property rights infringement. A panel convened by Brazil, India and South Africa yesterday at the World Trade Organization looked at the implications of a new definition of such products at the neighbouring World Health Organization. Continue reading -> World Health Assembly Agrees To Reinvigorate Plan Of Action To Boost R&D, Access 25/05/2018 Catherine Saez Ten years after the adoption of a World Health Organization plan of action meant to stimulate innovation for diseases that disproportionately affect developing countries, and with very little to show for it since, delegates at the World Health Assembly this week agreed to a number of recommendations to reinvigorate the effort. How to finance the implementation of those recommendations, however, is unclear. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Substandard, Falsified Medicines Not About IP, Geneva Experts Say 06/06/2018 Catherine Saez Falsified and substandard medical products continue to be a global concern, and how those products are characterised is important to avoid confusion, particularly with intellectual property rights infringement. A panel convened by Brazil, India and South Africa yesterday at the World Trade Organization looked at the implications of a new definition of such products at the neighbouring World Health Organization. Continue reading -> World Health Assembly Agrees To Reinvigorate Plan Of Action To Boost R&D, Access 25/05/2018 Catherine Saez Ten years after the adoption of a World Health Organization plan of action meant to stimulate innovation for diseases that disproportionately affect developing countries, and with very little to show for it since, delegates at the World Health Assembly this week agreed to a number of recommendations to reinvigorate the effort. How to finance the implementation of those recommendations, however, is unclear. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
World Health Assembly Agrees To Reinvigorate Plan Of Action To Boost R&D, Access 25/05/2018 Catherine Saez Ten years after the adoption of a World Health Organization plan of action meant to stimulate innovation for diseases that disproportionately affect developing countries, and with very little to show for it since, delegates at the World Health Assembly this week agreed to a number of recommendations to reinvigorate the effort. How to finance the implementation of those recommendations, however, is unclear. Continue reading -> Posts navigation Older postsNewer posts